Ascentage Pharma Group International (AAPG): Price-to-Revenue Coefficient

Corporate company logo of Ascentage Pharma Corp (AAPG)

The prospects of Ascentage Pharma Group (AAPG) depend on the international recognition of olverembatinib and expansion into the US. Historical P/S dynamics confirm market expectations, where the current parameter equals 8.50. Growth is based on the global promotion of targeted drugs and alliances with big pharma. A positive forecast is supported by the development of apoptosis inhibitors aimed at combating tumor resistance within the framework of innovative R&D.

AAPG Ascentage: P/S Multiple in the range 01/25/2025 - 11/13/2026

Ascentage (AAPG) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Stock Price ascentage.com|AAPG - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Ascentage|AAPG - Enterprise Value
- company book value details:
Accounting Value per Share Ascentage Pharma|AAPG - Book Capitalization|Market-to-Book Ratio ascentage.com|AAPG - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio Ascentage Pharma Group|AAPG - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Ascentage Pharma Corp|AAPG - Company Aggregate Debts|Debts to Book Capitalization Ascentage|AAPG - Company Long-Term Debts|Short-Term Indebtedness Ascentage Pharma|Immediate Liquidity ascentage.com
- business earnings and investment ratios data:
AAPG - Net Income|Expected Net Income Ascentage Pharma Group|AAPG - Price to Earnings Ratio|Price to Expected Earnings Ratio Ascentage Pharma Group International|AAPG - PEG Multiple|Business Value to Operating Income Before Depreciation Ascentage|AAPG - Operating profit EBITDA|Net earnings per share (EPS TTM) Ascentage Pharma|AAPG - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months ascentage.com|AAPG - Earnings per share growth in current year|Expected earnings per share growth for next year Ascentage Pharma Group
- issuer revenue and sales details:
AAPG - Revenue and Sales Volume|Projected Sales Volume ascentage.com|AAPG - Market Cap to Revenue|Forward Price to Sales Ascentage
General company analysis:AAPG ascentage.com
Manufactured products of Ascentage Pharma Group International

To isolate fundamental stability from market noise, the ratio of market capitalization to annual sales is utilized, allowing for the valuation of each unit of revenue without accounting distortions. Analyzing the price-to-sales multiple helps align current investor expectations with the commercialization potential of olverembatinib and the expansion prospects of Ascentage Pharma Group (AAPG) into the US market.

Competing companies

P/S Multiple beigene.com (ONC)|Price-to-Revenue Ratio Halozyme HALO|Price-to-Revenue Coefficient Revolution Medicines Inc (RVMD)|CG Oncology Corp - P/S Multiple|UroGen Pharma Corp (URGN) - Market Cap to Revenue|BCAX: P/S Multiple|Price to Sales personalis.com (PSNL)|Price-to-Revenue Ratio Erasca|Market Cap to Revenue Ratio DCTH (Delcath Systems Inc)|Market Cap to Revenue YMAB (YmAbs)|Market Cap to Sales Volume AURA|P/S Multiple CADL (Candel Therapeutics, Inc.)|P/S Multiple accuray.com ARAY|SELLAS Life Sciences Group Inc. - P/S Multiple|Price-to-Revenue Multiple Actuate Therapeutics Inc. (ACTU)|CTOR: P/S Multiple|Price to Sales TuHURA Biosciences (HURA)|Market Cap to Revenue TARA|FATE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Aadi Bioscience Inc (WHWK)|TCRX: Price-to-Sales Ratio|P/S Multiple CSBR (Champions Oncology, Inc.)|Market Capitalization-to-Revenue Ratio XBIT|CEL-SCI Corp - P/S Multiple|OSTX - P/S Multiple|Radiopharm Theranostics (RADX) - Price-to-Revenue Ratio|Artiva Biotherapeutics - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Adlai Nortye Ltd|Market Cap to Revenue Veru Corporation (VERU)|P/S Multiple TPST|P/S Multiple xiliotx.com (XLO)|Renovaro - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio MURA|Kairos Pharma Inc - P/S Multiple|Price-to-Revenue Multiple OnKure Therapeutics Inc (OKUR)|w2.cytomed.sg (GDTC) - Price-to-Revenue Ratio|Curis - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Apollomics Inc.|Price to Sales Tharimmune Inc THAR|Market Cap to Revenue ADVB (Advanced Biomed Inc)|P/S Multiple Genprex Inc (GNPX)|Price-to-Revenue Ratio Calidi Biotherapeutics, Inc. CLDI|SBFM (sunshinebiopharma.com) - Price-to-Sales Ratio|Xenetic Bio - P/S Multiple|SLRX - P/S Multiple|PPBT: P/S Multiple|American Oncology Network, Inc. (AONC) - P/S Multiple|Price-to-Revenue Ratio BeiGene, Ltd.|checkpointtx.com - Price-to-Sales Ratio|P/S Multiple ELEV|icadmed.com (ICAD) - Price-to-Revenue Multiple|P/S Multiple IKNA (Ikena Oncology)|NTBL - Market Cap to Revenue|Viracta - P/S Multiple|MOR - P/S Multiple|NAYA Biosciences Inc. (NAYA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio AAPGV